![Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone | British Journal of Cancer Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2014.531/MediaObjects/41416_2014_Article_BFbjc2014531_Fig1_HTML.jpg)
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone | British Journal of Cancer
![Cancers | Free Full-Text | Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review Cancers | Free Full-Text | Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review](https://www.mdpi.com/cancers/cancers-14-03773/article_deploy/html/images/cancers-14-03773-g001.png)
Cancers | Free Full-Text | Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review
![Abiraterone: New Drug in the Treatment of Metastatic Castration-resistant Prostate Cancer - The ASCO Post Abiraterone: New Drug in the Treatment of Metastatic Castration-resistant Prostate Cancer - The ASCO Post](https://ascopost.com/media/154817/3.3.36_fig.jpg)
Abiraterone: New Drug in the Treatment of Metastatic Castration-resistant Prostate Cancer - The ASCO Post
![Abiraterone: New Drug in the Treatment of Metastatic Castration-resistant Prostate Cancer - The ASCO Post Abiraterone: New Drug in the Treatment of Metastatic Castration-resistant Prostate Cancer - The ASCO Post](https://ascopost.com/media/154812/3.3.36_chart.jpg)
Abiraterone: New Drug in the Treatment of Metastatic Castration-resistant Prostate Cancer - The ASCO Post
![Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design - Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design -](https://www.thelancet.com/cms/attachment/baa60d08-a449-46ca-90a9-bf2ed7743ab6/gr2.jpg)
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design -
A Phase II Study of Increased-Dose Abiraterone Acetate in Patients with Castration Resistant Prostate Cancer (CRPC)
ZYTIGA® (abiraterone acetate) Tablets 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the informati
![Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design - Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design -](https://www.thelancet.com/cms/attachment/0cfa3c57-0839-4ef7-95a3-e193cca3bf33/gr1.gif)
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design -
![Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study - The Lancet ... Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study - The Lancet ...](https://www.thelancet.com/cms/attachment/4a0e6e0e-f6ae-43c3-8ef4-004c37a99115/gr1.gif)
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study - The Lancet ...
![Cancers | Free Full-Text | The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice Cancers | Free Full-Text | The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice](https://pub.mdpi-res.com/cancers/cancers-13-03518/article_deploy/html/images/cancers-13-03518-g001.png?1626255952)
Cancers | Free Full-Text | The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice
![Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol | BMJ Open Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol | BMJ Open](https://bmjopen.bmj.com/content/bmjopen/9/9/e030218/F1.large.jpg)
Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol | BMJ Open
![Clinical effectiveness of abiraterone acetate plus prednisone for the... | Download Scientific Diagram Clinical effectiveness of abiraterone acetate plus prednisone for the... | Download Scientific Diagram](https://www.researchgate.net/publication/359821040/figure/fig1/AS:1153147112292352@1651943104121/Clinical-effectiveness-of-abiraterone-acetate-plus-prednisone-for-the-treatment-of.png)
Clinical effectiveness of abiraterone acetate plus prednisone for the... | Download Scientific Diagram
![Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer - Annals of Oncology Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/543582d9-7db6-4997-8ed6-989c673ae7e9/gr1.jpg)
Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer - Annals of Oncology
![Treatment Sequencing of Abiraterone Acetate plus Prednisone and Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer - touchONCOLOGY Treatment Sequencing of Abiraterone Acetate plus Prednisone and Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer - touchONCOLOGY](https://touchoncology.com/wp-content/uploads/sites/2/2019/10/Maughan_T1C-1.jpg)